These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 8685346)

  • 21. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.
    Zakian KL; Sircar K; Hricak H; Chen HN; Shukla-Dave A; Eberhardt S; Muruganandham M; Ebora L; Kattan MW; Reuter VE; Scardino PT; Koutcher JA
    Radiology; 2005 Mar; 234(3):804-14. PubMed ID: 15734935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI spectroscopy in screening of prostate cancer.
    Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
    Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Spectroscopic imaging (1H-2D-CSI) of the prostate: sequence optimization and correlation with histopathological results].
    Stanka M; Eltze E; Semjonow A; Sievert KD; Maier A; Pfleiderer B
    Rofo; 2000 Jul; 172(7):623-9. PubMed ID: 10962989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.
    Carlani M; Mancino S; Bonanno E; Finazzi Agrò E; Simonetti G
    Radiol Med; 2008 Aug; 113(5):670-88. PubMed ID: 18493829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study.
    Scheidler J; Hricak H; Vigneron DB; Yu KK; Sokolov DL; Huang LR; Zaloudek CJ; Nelson SJ; Carroll PR; Kurhanewicz J
    Radiology; 1999 Nov; 213(2):473-80. PubMed ID: 10551229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system.
    Jung JA; Coakley FV; Vigneron DB; Swanson MG; Qayyum A; Weinberg V; Jones KD; Carroll PR; Kurhanewicz J
    Radiology; 2004 Dec; 233(3):701-8. PubMed ID: 15564406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [1H magnetic resonance spectroscopy of the prostate].
    Mueller-Lisse UG; Scherr M
    Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.
    Westphalen AC; Coakley FV; Qayyum A; Swanson M; Simko JP; Lu Y; Zhao S; Carroll PR; Yeh BM; Kurhanewicz J
    Radiology; 2008 Jan; 246(1):177-84. PubMed ID: 18024434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations.
    Shukla-Dave A; Hricak H; Eberhardt SC; Olgac S; Muruganandham M; Scardino PT; Reuter VE; Koutcher JA; Zakian KL
    Radiology; 2004 Jun; 231(3):717-24. PubMed ID: 15163811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
    Zbýň Š; Krššák M; Memarsadeghi M; Gholami B; Haitel A; Weber M; Helbich TH; Trattnig S; Moser E; Gruber S
    Rofo; 2014 Jul; 186(7):698-702. PubMed ID: 24940925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.
    Crehange G; Maingon P; Gauthier M; Parfait S; Cochet A; Mirjolet C; Bonnetain F; Cormier L; Brunotte F; Walker P
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e407-13. PubMed ID: 21605949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy.
    Valentini AL; Gui B; D'Agostino GR; Mattiucci G; Clementi V; Di Molfetta IV; Bonomo P; Mantini G
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):719-24. PubMed ID: 22436789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study.
    Mueller-Lisse UG; Vigneron DB; Hricak H; Swanson MG; Carroll PR; Bessette A; Scheidler J; Srivastava A; Males RG; Cha I; Kurhanewicz J
    Radiology; 2001 Nov; 221(2):380-90. PubMed ID: 11687679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
    García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM
    Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
    Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
    Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.
    Yu KK; Scheidler J; Hricak H; Vigneron DB; Zaloudek CJ; Males RG; Nelson SJ; Carroll PR; Kurhanewicz J
    Radiology; 1999 Nov; 213(2):481-8. PubMed ID: 10551230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.
    Casciani E; Polettini E; Bertini L; Emiliozzi P; Amini M; Pansadoro V; Gualdi GF
    Radiol Med; 2004; 108(5-6):530-41. PubMed ID: 15722999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.
    Fütterer JJ; Heijmink SW; Scheenen TW; Veltman J; Huisman HJ; Vos P; Hulsbergen-Van de Kaa CA; Witjes JA; Krabbe PF; Heerschap A; Barentsz JO
    Radiology; 2006 Nov; 241(2):449-58. PubMed ID: 16966484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy.
    Weis J; Ahlström H; Hlavcak P; Häggman M; Ortiz-Nieto F; Bergman A
    Magn Reson Imaging; 2009 Jan; 27(1):87-93. PubMed ID: 18599244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate.
    Kobus T; van der Laak JA; Maas MC; Hambrock T; Bruggink CC; Hulsbergen-van de Kaa CA; Scheenen TW; Heerschap A
    Radiology; 2016 Mar; 278(3):801-11. PubMed ID: 26418614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.